polatuzumab vedotin
roche
['cml', 'dlbcl', 'lymsm', 'pola']
cart in r/r dlbcl and the role of bridging: rt as a possibility (sp when using pola 1l) antigen exposure and tmtv. if cr infusion of cart: 1y efs 60%. bridging may also mitigate ae such as icans. #17icml #lymsm
hematologa en Fleming, lymphoma fan, mama de Luchi, un poco yogi y mucha acuarela!